HOWL logo

WEREWOLF THERAPEUTICS INC

HOWLNASDAQ
🏆 #4265 by market capUS Equity
$1.08▲ $0.00 (+0.00%)
Latest quote
🔔
Track HOWL
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.0%
7d▲ 5.9%
14d▲ 8.6%
30d▲ 19.2%
ytd▲ 71.4%
1y▼ 31.2%
🏦Market Cap
$52M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
2.5x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.07 – $1.10
52-Week Range
$0.27 – $1.72
Volume (shares)
6,239
Avg Volume (shares)
—
Shares Outstanding
48.6M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
$21M
P/E Ratio
—
P/S Ratio
2.5x
EPS (TTM)
$-0.73
Dividend Yield
—
Dilution (1yr)
+5.2%
HOWL logo

WEREWOLF THERAPEUTICS INC

HOWL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
3.8%▼ −95.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$61M▼ −17.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$60M▲ +6.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.8M▲ +5.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$19M▼ −$55M YoY
StockOtter · stockotter.space

About WEREWOLF THERAPEUTICS INC

Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.